Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Febuxostat Viatris (previously Febuxostat Mylan), febuxostat, Date of authorisation: 15/06/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Waylivra, volanesorsen, Date of authorisation: 03/05/2019, Revision: 7, Status: Authorised

PSUSA/00009326/202411

PSUSA/00002047/202412

PSUSA/00001013/202411

PSUSA/00002257/202412

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Sugammadex Fresenius Kabi, sugammadex, Date of authorisation: 15/07/2022, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Epoetin Alfa Hexal, epoetin alfa, Date of authorisation: 27/08/2007, Revision: 27, Status: Authorised